• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Obstetrics

High frequency of germline mutations observed in triple negative breast cancers

byKhang DinhandDavid Wang
December 6, 2014
in Obstetrics, Oncology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. A total of 14.6% of patients with triple negative breast cancers were found to have deleterious mutations in cancer susceptibility genes.

2. Of these patients with mutations, 11.2% were of the BRCA1/2 genes while 3.7% of patients had mutations in 15 other susceptibility genes.

Evidence Rating Level: 3 (Average)

Study Rundown: Triple negative breast cancer (TNBC) are a breast cancer subtype that lack expression of estrogen receptor, progesterone receptor, or human epidermal growth factor receptor 2. TNBC represents 12-15% of all breast cancers and are associated with worse outcomes compared to other breast cancer subtypes. Previous studies have demonstrated a high frequency of germline mutations in the BRCA1/2 genes in TNBC; however, the prevalence of deleterious mutations in other cancer predisposition genes are not well established. The purpose of this trial was to determine the frequency of germline mutations in a large cohort of TNBC patients. Germline DNA were collected from over 1,800 TNBC patients and analyzed for mutations in 17 cancer predisposition genes. The authors demonstrated that 11.2% of TNBC patients had mutations in BRCA1/2 while 3.7% had mutations in one other cancer susceptibility genes. Patients with deleterious mutations in these genes were statistically more likely to be younger compared to those without mutations. Unlike with BRCA mutations, patients with non-BRCA mutations did not have significant family history of breast or ovarian cancers. The high frequency of BRCA mutations observed in this trial support the use of germline BRCA genetic testing in patients with TNBC, regardless of family history. However, additional information on the penetrance of non-BRCA mutations are required before the clinical utility of these tests can be assessed. A major limitation of this study is that 97% of the included patients were white, while only 1.9% were African American, despite the latter being a risk factor for TNBC.

Click to read the study in the Journal of Clinical Oncology

Relevant reading: Genetic Susceptibility to Triple Negative Breast Cancer

In-Depth [case-control study]: In this study, germline DNA samples from 1824 female patients from 11 centers in the United States, Germany, Finland, Greece, and United Kingdom were collected and sequenced for 17 cancer susceptibility genes. Of these patients, 1762 (97%) were white, 34 (1.9%) were black, 10 (0.6%) were Asian, and 10 (0.6%) were Hispanic. Overall, 271 deleterious mutations were found in 267 patients (14.6%). Of these mutations, BRCA1 was the most frequent with 155 (57%) patients, followed by BRCA2 with 49 (18%) patients, and 67 (25%) with non-BRCA mutations. Patients diagnosed with TNBC at an age younger than 40 years represented 38% of all deleterious mutations. The mean age at diagnosis was younger for deleterious mutations versus wild-type genes (45 vs 52 years, P<0.001). Patients with BRCA1 mutations were more likely to have a family history of breast (50%, P<0.001) and ovarian (18%, P<0.001) cancer. Patients with other mutations did not have statistically significant associated family histories.

RELATED REPORTS

ACKR1 variant increases risk of azathioprine-related hematopoietic toxicity

#VisualAbstract: Whole-genome sequencing changes clinical management in significant number of critically ill infants

#VisualAbstract: Adjuvant capecitabine improves long-term survival in early breast cancer

More from this author: Afatinib shows increased progression-free survival in non-small-cell lung cancer, New method may predict response to chemotherapy for lung cancer, Escalated-dose radiotherapy did not increase survival in prostate cancer

Image: PD

©2014 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. No article should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2 Minute Medicine, Inc.

Tags: geneticstriple negative breast cancer
Previous Post

Meta-analysis suggests endovascular therapy improves stroke outcomes

Next Post

Adherence to a Mediterranean diet linked to longer telomere length

RelatedReports

Nearly Half of All Pediatric Buprenorphine Exposures Result in Hospitalization
Chronic Disease

ACKR1 variant increases risk of azathioprine-related hematopoietic toxicity

June 30, 2022
#VisualAbstract: Only one quarter of benzodiazepine prescriptions in youth are for approved indication
StudyGraphics

#VisualAbstract: Whole-genome sequencing changes clinical management in significant number of critically ill infants

June 10, 2022
#VisualAbstract: Adjuvant capecitabine improves long-term survival in early breast cancer
StudyGraphics

#VisualAbstract: Adjuvant capecitabine improves long-term survival in early breast cancer

May 18, 2022
Oophorectomy associated with reduced cancer risk and all-cause mortality for BRCA1/2 patients
Chronic Disease

Whole-genome sequencing changes clinical management in significant number of critically ill infants

December 21, 2021
Next Post
BRAF V600E mutations linked with increased mortality in thyroid cancer

Adherence to a Mediterranean diet linked to longer telomere length

Exercise improves aromatase inhibitor-induced arthralgia in breast cancer survivors

Exercise improves aromatase inhibitor-induced arthralgia in breast cancer survivors

Dexamethasone shows comparable efficacy to prednisone/prednisolone in pediatric asthma

Misoprostol not linked to peripartum asthma exacerbations

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Sickle cell trait associated with preexisting kidney comorbidities and increased COVID-19 mortality
  • Adding atezolizumab to standard of care treatment for human epidermal growth factor receptor 2 (HER2) positive early breast cancer does not improve pathologic response outcomes
  • FOLFOX combined with nivolumab and trastuzumab in ERBB2-positive esophagogastric adenocarcinoma is an emerging therapy option
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.